Adicet Bio, Inc. Cash and Restricted Cash
Adicet Bio, Inc. (ACET) had Cash and Restricted Cash of $36.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $36.00M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $39.11M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $41.79M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $32.00M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $36.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $39.11M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $41.79M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $32.00M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $37.62M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $31.04M 10-Q · filed 2026-05-13 | |
| 2024-12-31 | $59.40M 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $105.48M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $224.07M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $247.59M 10-Q · filed 2025-05-06 | |
| 2023-12-31 | $159.71M 10-K · filed 2026-03-12 | |
| 2023-09-30 | $183.26M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $205.46M 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $231.64M 10-Q · filed 2024-05-14 | |
| 2022-12-31 | $257.66M 10-K · filed 2025-03-06 | |
| 2022-09-30 | $282.68M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $260.64M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $278.03M 10-Q · filed 2023-05-09 | |
| 2021-12-31 | $277.69M 10-K · filed 2024-03-19 | |
| 2021-09-30 | $196.75M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $213.25M 10-Q · filed 2022-08-10 | |
| 2021-03-31 | $226.44M 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $88.86M 10-K · filed 2023-03-15 | |
| 2020-09-30 | $89.49M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $22.55M 10-Q · filed 2021-08-12 | $71.13M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $11.02M 10-Q · filed 2021-05-17 | $61.48M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $14.89M 10-K · filed 2022-03-15 | $34.02M 10-K · filed 2020-03-12 |
| 2019-09-30 | $27.29M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $21.37M 10-Q · filed 2020-07-30 | |
| 2019-03-31 | $7.18M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $13.76M 10-K · filed 2021-03-12 | $7.13M 10-K · filed 2020-03-12 |
| 2017-12-31 | $36.95M 10-K · filed 2021-03-12 | $53.35M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |